Cultivating an Innovative Ecosystem for Infectious Disease Prevention and Treatment

On June 24^th, Beijing Ditan Hospital, Capital Medical University, recently signed a strategic cooperation agreement with Gilead Sciences. The collaboration will focus on key infectious diseases such as viral hepatitis and HIV/AIDS, encompassing clinical research, clinical translation, and public health capacity building. Through a collaborative "hospital-research-industry" innovation model, the partnership aims to establish new paradigms for infectious disease control, advancing the Healthy China 2030 initiative.

As the National Center for Infectious Diseases, Beijing Ditan Hospital is a 3A hospital specializing in infection and infectious diseases. It serves as a benchmark in complex and critical care, multi-center clinical research, and public health emergency response.

Prof. Jin Ronghua, President of Beijing Ditan Hospital, stated: "Our hospital is committed to a 'people-centered' healthcare philosophy. Through this collaboration with Gilead, we will combine our expertise in antiviral medicine to develop innovative early screening and treatment approaches, refine clinical practices using real-world evidence, and deliver breakthrough therapies to patients more quickly."

Mr. Jin Fangqian, Vice President of Gilead Sciences and General Manager of Gilead China, stated: "For over 30 years, Gilead has been committed to patient-centric breakthroughs in HIV, viral hepatitis, oncology, and inflammatory diseases. Our partnership with Beijing Ditan Hospital combines our respective strengths in resources and antiviral research to develop innovative care models and foster a healthcare ecosystem that improves public health."

This agreement elevates the partnership from standalone projects to a strategic, systematic collaboration. Prof. Jin Ronghua emphasized: "From pioneering HIV precision medicine to establishing a comprehensive framework for diagnosis, R&D, and health services, this partnership embodies the shared mission of hospitals, academia, and industry." As a landmark alliance between China's national leader in infectious diseases and a global innovator in antiviral therapies, it sets a new benchmark for cross-sector collaboration and advances Healthy China 2030 while contributing to global health equity.